{
  "id": 16674425,
  "title": "Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stock",
  "url": "https://urgent.news/2026/10/26/korro-bio-10-owner-lynx1-capital-management-lp-buys-884-751-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-26T23:01:20.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/korro-bio-10-owner-lynx1-capital-management-lp-buys-884751-stock-93CH-4973925"
  },
  "original_language": "en",
  "account": "Lynx1 Capital Management LP, a 10% owner and director of Korro Bio, Inc., recently purchased $884,751 worth of common stock in the company. The shares were acquired over a few days in late October 2026 at prices ranging from $9.6764 to $12.1061 per share. Lynx1 Capital Management LP's stake in Korro Bio increased as a result. The company's stock saw a 35% increase over the past week, currently trading at $12.02. Lynx1 Capital Management LP, acting through Lynx1 Master Fund LP, now holds 1,624,789 shares of Korro Bio. This acquisition comes after the company announced the start of a Phase 1/2 clinical trial for KRRO-121, targeting hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. Both H.C. Wainwright and Raymond James have maintained positive outlooks on Korro Bio, with price targets of $15.00 and $23.00 respectively.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}